清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia

达沙替尼 医学 慢性粒细胞白血病 髓系白血病 毒品假日 内科学 期限(时间) 肿瘤科 儿科 免疫学 伊马替尼 人类免疫缺陷病毒(HIV) 量子力学 物理
作者
Georgina Gener-Ricos,Fadi Haddad,Koji Sasaki,Ghayas C. Issa,Jeffrey Skinner,Koichi Takahashi,Lucia Masárová,Jan A. Burger,Gautam Borthakur,Prithviraj Bose,Guillermo Garcia‐Manero,Elias Jabbour,Hagop Kantarjian
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 1493-1494 被引量:2
标识
DOI:10.1182/blood-2022-167764
摘要

Background: Dasatinib is a second generation BCR::ABL1 tyrosine kinase inhibitor approved at the dose of 100 mg daily for the frontline therapy of patients with chronic myeloid leukemia in chronic phase (CML-CP). Low-dose dasatinib (50mg daily) has been previously reported to be effective and better tolerated compared to the standard dose. Here, we report updated data with longer follow-up of patients with newly diagnosed CML-CP treated with dasatinib 50 mg daily. Method: Patients with newly diagnosed CML-CP who were treated with low-dose dasatinib (50 mg daily) were included. Response criteria were standards defined in previous protocols. The overall survival (OS) was calculated from the start date of the therapy to the date of death from any cause at any time or date of last follow-up; the event-free survival (EFS) to the date of any of the events while on study as defined in the IRIS study; failure-free survival (FFS) was calculated from the start date of therapy to the dates of treatment discontinuation for any reason except of treatment-free remission; transformation-free survival (TFS), to the date of transformation to accelerated or blast phases during study. Patients on low-dose dasatinib who had suboptimal response by ELN 2013 criteria had an option to increase the dose to 100 mg/day as well as decreasing the dose to 20 mg/day in case of significant toxicity. Results: Eighty-three patients were included, with a median age of 47 years (range, 20-84); 48% were males (Table 1). By Sokal risk score, most of the patients had low-risk (65%) or intermediate-risk (29%) disease. Eighty-one patients were evaluable for response. At 3 months, 78 (96%) patients achieved BCR::ABL1/ABL1 ≤10%, and 62 (77%) patients achieved BCR::ABL1/ABL1 ≤1%. The 12-month major molecular response (MMR) rate was 81%. The cumulative incidence of molecular response (MR)4, MR4.5, and complete molecular response (CMR) rates within 1 year were 63%, 53%, and 46%, respectively. After a median follow-up of 5 years, the 5-year FFS, EFS, TFS and OS rates were 88%, 97%, 100% and 98%, respectively. Treatment was well-tolerated overall; the rates of pleural effusion of any Grade and of Grade 3-4 were 5% and 3%, respectively. Due to safety concerns, 5 (6%) patients had treatment interruption within 12 months of starting therapy and for a median of 10 days (range, 7-22 days). At 12 months, 2 patients had a dose reduction to 20 mg and 40 mg, respectively. The mean daily dose administered was 49 mg. Conclusions: With longer follow-up, dasatinib 50 mg daily continues to be effective and safe in newly diagnosed CML-CP and therefore should be considered as standard of care. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝应助ffw采纳,获得10
2秒前
量子星尘发布了新的文献求助10
7秒前
huangzsdy完成签到,获得积分0
7秒前
15秒前
wanci应助陳某采纳,获得10
17秒前
一早完成签到,获得积分10
17秒前
ch发布了新的文献求助10
21秒前
NexusExplorer应助科研通管家采纳,获得10
23秒前
28秒前
airtermis完成签到 ,获得积分10
31秒前
li8888li8888完成签到 ,获得积分10
42秒前
53秒前
Otter完成签到,获得积分10
54秒前
li8888lili8888完成签到 ,获得积分10
56秒前
陳某发布了新的文献求助10
59秒前
闪闪绝施发布了新的文献求助20
1分钟前
ch完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
yellowonion完成签到 ,获得积分10
1分钟前
披着羊皮的狼完成签到 ,获得积分10
2分钟前
绿色心情完成签到 ,获得积分10
2分钟前
领导范儿应助科研通管家采纳,获得10
2分钟前
呱同志完成签到 ,获得积分10
2分钟前
旅人完成签到 ,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
偷得浮生半日闲完成签到,获得积分10
2分钟前
clientprogram应助Lee_yuan采纳,获得30
3分钟前
Able完成签到,获得积分10
3分钟前
ch发布了新的文献求助10
3分钟前
量子星尘发布了新的文献求助10
3分钟前
刘丰完成签到 ,获得积分10
3分钟前
Beatrice完成签到,获得积分10
4分钟前
zhdjj完成签到 ,获得积分10
4分钟前
情怀应助科研通管家采纳,获得10
4分钟前
量子星尘发布了新的文献求助10
4分钟前
4分钟前
5分钟前
5分钟前
Lny发布了新的文献求助20
5分钟前
可夫司机完成签到 ,获得积分10
5分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976713
求助须知:如何正确求助?哪些是违规求助? 3520805
关于积分的说明 11204819
捐赠科研通 3257584
什么是DOI,文献DOI怎么找? 1798771
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806648